Regulatory Filing
Wanbury Receives Six USFDA Form 483 Observations After cGMP Inspection at Andhra Pradesh Facility
NSE
wanbury
BSE
524212
- Wanbury Limited has informed the stock exchanges that the United States Food and Drug Administration (USFDA)completed a routine Current Good Manufacturing Practices (cGMP) inspection at its Tanuku manufacturing facility in West Godavari District, Andhra Pradesh, between July 13 and July 17, 2026.
- At the conclusion of the inspection, the USFDA issued a Form 483 with six observations. The company stated that it will submit its response to the regulator within the stipulated timeline.Â
PRICE-SENSITIVE TRIGGER
Event: Completion of a routine USFDA cGMP inspection at Wanbury’s Tanuku manufacturing facility with issuance of Form 483 containing six observations.
Type: Regulatory Filing
Impact: Neutral
Immediate Effect: The inspection has concluded, and the company is required to address the six observations raised by the USFDA. No import alert, warning letter, or regulatory enforcement action has been disclosed.Â
highlight:
- The USFDA completed its inspection of Wanbury’s Tanuku facility and issued a Form 483 with six observations, to which the company will respond within the prescribed timeline.Â
What Happened ?
Wanbury Limited announced that the USFDA conducted a routine cGMP inspection at its manufacturing facility located in Tanuku, West Godavari District, Andhra Pradesh, from July 13 to July 17, 2026.
Following the completion of the inspection, the regulator issued Form 483 containing six observations. The company has stated that it will submit its response to the USFDA within the stipulated period and will keep the stock exchanges informed of any further developments.
Key details
USFDA Inspection Outcome:
- Routine cGMP inspection conducted between July 13 and July 17, 2026.
- Inspection covered Wanbury’s manufacturing facility at Tanuku, West Godavari District, Andhra Pradesh.
- The USFDA issued Form 483 with six observations at the conclusion of the inspection.
- Wanbury will submit its response to the regulator within the prescribed timeline.
- The company has committed to updating the stock exchanges regarding any subsequent developments.
Regulatory Context:
- A Form 483 is issued when USFDA investigators identify conditions that may require corrective action during an inspection. The observations are preliminary in nature and do not represent a final regulatory determination. The company’s response and subsequent review by the USFDA will determine the final outcome.
Note:
- The filing does not disclose the nature of the six observations, any production impact, warning letter, import alert, Official Action Indicated (OAI) classification, or financial implications arising from the inspection.Â
Risk Analysis
Summary:
- The inspection outcome introduces a regulatory compliance matter that will remain under investor watch until the USFDA reviews the company’s corrective action response. At this stage, no regulatory enforcement action has been announced.
Key Risks:
- Six Form 483 observations require timely corrective action.
- The nature of the observations has not been disclosed.
- Delays or inadequate responses could result in additional regulatory scrutiny.
- Future USFDA actions will depend on the adequacy of the company’s remediation measures.
Worst Case:
- If the USFDA determines that the corrective actions are insufficient, the facility could face further regulatory action, including warning letters or additional compliance measures, potentially affecting operations or exports to the U.S.
Risk Level: Medium
Company Commentary
- Wanbury confirmed completion of the routine USFDA cGMP inspection.
- The company acknowledged receipt of Form 483 with six observations.
- Management stated that it will respond to the observations within the stipulated timeframe.
- Wanbury also confirmed that it will keep the stock exchanges informed of any further updates related to the inspection.
Official Exchange Filing: Wanbury Limited
